Study Phase 2

SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes

Trial Information

Generic NameGolimumabProduct NameSIMPONI®Therapeutic AreaImmune System DiseasesEnrollment84% Female41.7%% White85.7%
Product ClassAntirheumatic Agents - Biologic Response ModifiersSponsor Protocol NumberCNTO148DML2001Data PartnerJohnson & JohnsonCondition StudiedDiabetes Mellitus, Type 1Mean/Median Age (Years)13.4

Supporting Documentation

  • Collected Datasets Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available


Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.